SLC22A3 and prostate carcinoma: It is noteworthy that SLC22A3 knockout alone does not affect prostate cancer cell proliferation and survival (Figure 1F–J), suggesting that SLC22A3 is more likely to affect prostate cancer progression via its effects on drug efficacy.